



DIVISION OF CLINICAL MICROBIOLOGY
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
Indiana University Health
Indianapolis, IN 46202

Lyme Disease Testing at IU Health

June 30, 2020

Effective July 7, 2020, the IU Health Division of Clinical Microbiology will begin offering serological testing for Lyme disease. The tests offered include the VIDAS Lyme IgG II and the VIDAS Lyme IgM II assays, which offer high analytical sensitivity and specificity for the detection of IgG and IgM antibodies to *Borrelia burgdorferi*. The following questions and answers are meant to address specific information regarding this testing:

1. What are the Cerner orderables for this new in-house Lyme disease testing?

Lyme Disease Antibody IgG/IgM EIA – both IgG and IgM are detected in this combined test
Lyme Disease Antibody IgG EIA – only IgG is detected with this test

2. Does this testing require confirmation of POSITIVE or EQUIVOCAL results?

Yes! The U.S. Centers for Disease Control and Prevention recommends a two-tiered process for Lyme disease testing. The Lyme Disease Antibody IgG/IgM EIA, IgG EIA, and IgM EIA are the first-stage tests. **All Lyme Disease Antibody IgG-POSITIVE and Lyme Disease Antibody IgM-POSITIVE and -EQUIVOCAL specimens will be referred to ARUP Laboratories for confirmatory immunoblot testing.** For more information on those tests, please refer to:

- a. ARUP Laboratories *Borrelia burgdorferi* Antibody, IgG by Immunoblot:
<https://ltd.aruplab.com/Tests/Pub/0050255>
- b. ARUP Laboratories *Borrelia burgdorferi* Antibody, IgM by Immunoblot:
<https://ltd.aruplab.com/Tests/Pub/0050253>

3. What specimen(s) is/are acceptable for Lyme Disease Antibody testing at IU Health?

Serum.

*For more information, please contact the IU Health Division of Clinical Microbiology (317.491.6999).